Lexology November 26, 2024
Holland & Knight LLP

Highlights

  • Pursuant to new regulations issued by the U.S. Drug Enforcement Administration (DEA) and U.S. Department of Health and Human Services (HHS) (collectively, the Agencies) on Nov. 11, 2024, providers will be able to continue prescribing Schedule II-V controlled medications via telemedicine without an in-person evaluation until Dec. 31, 2025.
  • This is the third extension of the telemedicine flexibilities and is intended to maintain the status quo while the Agencies develop a longer-term solution.
  • The flexibilities are subject to the same requirements as previous extensions.

The U.S. Drug Enforcement Agency Administration (DEA) and U.S. Department of Health and Human Services (HHS) (collectively, the Agencies) on Nov. 11, 2024, issued a third extension of their telemedicine flexibilities for the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Govt Agencies, Patient / Consumer, Provider, Technology, Telehealth
Related Articles:
Improving patient outcomes and health care access in rural populations with patient engagement technology
MD Ally Improves 911 Emergency Calls With Telehealth
Addressing the mental health crisis with virtual on demand
Amwell’s Roy Schoenberg talks about telehealth and broader views of virtual care
Trinity Health expands virtual nursing to 26 hospitals, 11 states

Share This Article